{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:10:36Z","timestamp":1779120636960,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Carbapenem-resistant\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      (CRPA) and multidrug-resistant (MDR)\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      limit therapeutic options but have been sparsely documented in Ghana.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      From November 2023 to December 2024, we conducted a prospective cross-sectional study of\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      isolates from acute-care hospitals in Greater Accra, Ghana. Isolates were identified by matrix-assisted laser desorption ionization\u2013time of flight, and antimicrobial susceptibility was assessed by disk diffusion as per Clinical Laboratory Standard Institute guidelines. Meropenem-resistant isolates with positive carbapenemase phenotype were subjected to whole-genome sequencing. Multivariable logistic regression models identified risk factors for infections caused by MDR and\n                      <jats:italic toggle=\"yes\">carbapenemase-producing Pseudomonas aeruginosa<\/jats:italic>\n                      (CRPA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      accounted for 0.32% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 267\/83,589) of all bacterial infections identified from submitted clinical specimens and 2.82% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 267\/12,236) of culture-positive infections. Of the 267\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      isolates, 20.2% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 54\/267) were MDR and 13.5% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 36\/267) were CRPA. Amikacin retained the highest activity against\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      . The mean multiple antibiotic resistance index among MDR isolates (0.51 \u00b1 0.26) was significantly higher than that among non-MDR\n                      <jats:italic toggle=\"yes\">P.aeruginosa<\/jats:italic>\n                      isolates\u00a0(0.02 \u00b1 0.07;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), with a large between-group difference (Hedges\u2019\n                      <jats:italic toggle=\"yes\">g<\/jats:italic>\n                      = 3.70). Only one isolate (2.7%) harbored a single carbapenemase gene,\n                      <jats:italic toggle=\"yes\">blaNDM-1<\/jats:italic>\n                      . The remaining 35 carried a\n                      <jats:italic toggle=\"yes\">blaOXA-50<\/jats:italic>\n                      -type backbone that co-occurred with either class A carbapenemases (\n                      <jats:italic toggle=\"yes\">blaKPC<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 7],\n                      <jats:italic toggle=\"yes\">blaSME-1<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 4],\n                      <jats:italic toggle=\"yes\">blaGES-5<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1]) or class B metallo-\u03b2-lactamases (\n                      <jats:italic toggle=\"yes\">blaNDM-1<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 19],\n                      <jats:italic toggle=\"yes\">blaVIM-5<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 3],\n                      <jats:italic toggle=\"yes\">blaIMP-15<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1]).\n                      <jats:italic toggle=\"yes\">blaNDM-1<\/jats:italic>\n                      was the most dominant carbapenemase gene (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 20\/36) . Wound infection was the strongest predictor of MDR infections (adjusted odds ratio [aOR] = 3.01; 95% confidence interval (CI) = 1.43\u20134.47;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.001], whereas inpatient status was the strongest predictor of CRPA infection (aOR = 3.32; 95% CI = 0.98\u20134.09;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      MDR\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      and carbapenem Resistant\n                      <jats:italic toggle=\"yes\">P.aeruginosa<\/jats:italic>\n                      (CRPA), mostly\n                      <jats:italic toggle=\"yes\">blaNDM-1<\/jats:italic>\n                      producers, are major causes of infection in our setting. Restricting carbapenem use through stewardship and strengthening infection control is essential to limit CRPA spread.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10766294261436119","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:07:24Z","timestamp":1774714044000},"page":"215-225","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multicenter Surveillance of Antimicrobial Resistance Among\n                    <i>Pseudomonas aeruginosa<\/i>\n                    in Hospitals of the Greater Accra Region of Ghana"],"prefix":"10.1177","volume":"32","author":[{"given":"Francisca","family":"Duah","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, University of Ghana, Accra, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4922-4916","authenticated-orcid":false,"given":"Noah","family":"Obeng-Nkrumah","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science, School of Biomedical and Allied Health Sciences, University of Ghana, Legon, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly","family":"Egyir","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, Noguchi Memorial Institute of Medical Research, Accra, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Japheth","family":"Opintan","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, University of Ghana, Accra, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amoako","family":"Duah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Ghana Medical Center, Accra, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Boateng","sequence":"additional","affiliation":[{"name":"Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Magdalene","family":"Osei","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, University of Ghana, Accra, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Baffuor-Asare","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, University of Ghana, Accra, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Sampane-Donkor","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, University of Ghana, Accra, Ghana."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1159798"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.4314\/ejhs.v33i3.5"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-024-03640-7"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08230-y"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2048972"},{"key":"e_1_3_5_7_1","unstructured":"6.The World Health Organization. WHO Bacterial Priority Pathogens List 2024: Bacterial Pathogens of Public Health Importance to Guide Research Development and Strategies to Prevent and Control Antimicrobial Resistance. 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240093461 [Last accessed: September24 2025]."},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01056-1"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00329-9"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac060"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.4102\/ajlm.v12i1.2135"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310058"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2014.08.002"},{"key":"e_1_3_5_14_1","unstructured":"13.Weinstein MP Patel MDJB Bobenchik M et al. Performance Standards for Antimicrobial Susceptibility Testing CLSI M02 (2023)."},{"key":"e_1_3_5_15_1","unstructured":"14.Ii JSL Mathers AJ Bobenchik AM et al. Performance Standards for Antimicrobial Susceptibility Testing CLSI M100. 2023"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2017.134423"},{"key":"e_1_3_5_17_1","unstructured":"16.Manual. Genome Studio. Pub. No. 770-2007-002 Current as of 11 October 2010. 2010n.d."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/aem.46.1.165-170.1983"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci6010001"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/frabi.2023.1291046"},{"key":"e_1_3_5_22_1","unstructured":"21.Newman MJ Opintan DJA Sampane DE. Surveillance of antimicrobial drug resistance in Ghana. n.d."},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020255"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9976064"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820001454"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.21103\/Article13(3)_OA12"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0665-5"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-018-0370-9"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.10150"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0650-9"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2020.11.010"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10766294261436119","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10766294261436119","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10766294261436119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:45:13Z","timestamp":1779119113000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10766294261436119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1177\/10766294261436119"],"URL":"https:\/\/doi.org\/10.1177\/10766294261436119","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}